产品说明书
Mitoguazone
 |
同义名 : | Methylglyoxal-bis(guanylhydrazone);MGBG;Methyl-GAG |
| CAS号 : | 459-86-9 | |
| 货号 : | A995052 | |
| 分子式 : | C5H12N8 | |
| 纯度 : | 97% | |
| 分子量 : | 184.202 | |
| MDL号 : | MFCD00067519 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 7 mg/mL(38 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 50 mg/mL(271.44 mM)，配合低频超声，并调节pH至9 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Mitoguazone, also known as Methylglyoxal-bis(guanylhydrazone), is a synthetic polycarbony derivative with potent antitumour activity. Mitoguazone is a brain-permeable, competitive inhibitor of SAMDC, which disrupts polyamine biosynthesis. Mitoguazone induces apoptosis. Mitoguazone inhibits the integration of HIV DNA into the cellular DNA of monocytes and macrophages. Mitoguazone has therapeutic potential for acute leukaemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma[1][2][3][4].At concentrations as low as 0.5 μg/mL, Mitoguazone competitively inhibits spermine synthesis in lymphocytes. At concentrations of 30 μg/mL or higher, Mitoguazone inhibits protein synthesis and mitochondrial respiration[1].Mitoguazone induces apoptosis in Burkitt's lymphoma cell lines (Raji, Ramos and Daudi) and prostate carcinoma cell line (MPC 3), with apoptosis correlating with concentration and time, and induces p53-independent programmed cell death in human breast cancer MCF7 cell line[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
5.43mL 1.09mL 0.54mL |
27.14mL 5.43mL 2.71mL |
54.29mL 10.86mL 5.43mL |
| 参考文献 |
|---|